Foundayo’s first IQVIA daily data is low but explainable; Bernstein remains constructive on LLY’s oral obesity drug launch potential

Overview

This is a Bernstein company research report on Eli Lilly & Co (LLY.US) focused on the first IQVIA prescription data after the launch of the oral obesity drug Foundayo. The report notes that the first daily data had only 25 TRx on April 13, all at 0.8mg, but because daily IQVIA samples cover only part of retail pharmacies and exclude mail pharmacies and LillyDirect, this data carries significant understatement risk and cannot be treated as sufficient evidence of true demand.

Core views

Bernstein’s core view is that Foundayo’s first daily IQVIA data appears weak on the surface, but information content is limited; investors should wait for the first weekly data expected on April 17 and focus on capture rate, sample inclusion, and the daily-to-weekly uplift relationship. The report leans toward Lilly having stronger launch execution conditions, including the LillyDirect platform, Amazon same-day delivery, sales and medical team momentum, and sample programs, which may support Foundayo achieving a strong opening versus competitors in oral obesity drugs. The report also says Foundayo revenue above $2.0 billion in 2026 is still within reach, above the consensus estimate of around $1.49 billion.

Analysis framework

The report uses IQVIA daily and weekly prescription data as the core monitoring framework, comparing Foundayo’s launch-phase TRx/NRx with early Wegovy pill performance, and incorporates channel coverage, sample distribution, patient and physician friction, brand awareness, and seasonal launch-intent factors to interpret early prescription data. On valuation, it applies a 50/50 blend of DCF and FY27E adjusted EPS P/E multiple methods, with scenario analysis to assess Foundayo’s first-year revenue path in 2026.

Methodology notes

• Prescription data trackingComparison of IQVIA daily and weekly TRx/NRx

  Use daily and weekly prescription data to judge early Foundayo demand after launch, with sample coverage differences adjusted for.

  Daily TRx covers about 19,000 retail pharmacies and excludes mail pharmacies and LillyDirect, while weekly TRx covers about 40,000 pharmacies and includes LTC and Mail, so early daily data may severely understate true prescription demand.

• Competitive benchmarkEarly Foundayo versus Wegovy pill prescription comparison

  Compare TRx/NRx in the first few days of Foundayo’s launch with early data for Wegovy pill.

  The report notes that Wegovy pill data may also have capture-rate issues and cites Novo comments that the tracking script may capture only about 50% of demand when framing adjustment assumptions.

• Revenue scenario analysisFoundayo 2026 revenue scenarios

  Project full-year revenue based on new-patient starts, sample distribution, and early weekly trajectory.

  The report says it builds multiple scenarios to evaluate the conditions under which Foundayo can exceed $2.0 billion in revenue this year, while consensus expectations are about $1.49 billion.

• Valuation methodsBlended DCF and P/E multiple valuation

  Determine target price using DCF and FY27E adjusted EPS multiple methods with equal weighting.

  DCF assumptions include a 7.6% WACC, 5% FCFF CAGR through 2043, and 2.5% terminal growth rate; the multiple method uses 32x P/E of FY27E adjusted EPS; both methods are equally weighted, resulting in a $1,300 target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• LLY.US

  Core long asset and report subject

  Strengths

  Outperform rating, 1,300 USD target price, Foundayo potential revenue above 2.0 billion USD, LillyDirect and Amazon same-day delivery reduce channel friction, and strong execution from sales and medical teams.

  Weaknesses

  The first IQVIA daily data is only 25 TRx and appears weak on the surface, with unstable capture in the early period; stock performance has been weaker than SPX year-to-date through the report date.

  Comparison

  Compared with Novo’s Wegovy pill, Foundayo started later and has lower brand awareness, but Lilly’s prior Zepbound experience shows it can still scale successfully as a later entrant.

  Risks

  Obesity TAM, regulation, pricing, competition and fixed-dose combinations; manufacturing expansion constraints; value impairment from high-risk M&A or R&D progress.

• Wegovy pill

  Primary benchmark competitor

  Strengths

  Has brand awareness advantage and early prescription data can serve as a comparison baseline for Foundayo.

  Weaknesses

  The report notes its prescription data may capture only about 50% of demand, so the raw comparison may be distorted.

  Comparison

  Foundayo’s first daily data is far below the early bars of Wegovy pill, but Bernstein emphasizes that capture rates and channel structures differ and simple linear comparison is not appropriate.

  Risks

  If Wegovy pill maintains stronger early demand due to brand awareness, Foundayo expectations could be constrained.

• SPX

  Reference for relative rating

  Strengths

  Bernstein’s U.S. equity rating framework uses 12-month relative performance versus the S&P 500.

  Weaknesses

  LLY has underperformed SPX over the past month and year-to-date.

  Comparison

  The report tables show LLY YTD absolute return of -14.2% and relative return of -15.9%; 12-month absolute return of 21.8% and relative return of -7.0%.

  Risks

  If market risk appetite or index performance remains stronger than LLY, the relative return objective of Outperform may be difficult to achieve.

Key data

• First Foundayo daily TRx25 TRxData for April 13, all from the 0.8mg strength; the report believes this may be significantly understated.
• Daily IQVIA coverageAbout 19,000 retail pharmaciesMail-order pharmacies, including LillyDirect, are explicitly excluded.
• Weekly IQVIA coverageAbout 40,000 pharmaciesIncludes LTC and Mail, with generally higher capture than daily data.
• Expected first weekly data date2026-04-17The report expects the first weekly data to be available on April 17, 2026.
• Target price1,300.00 USDBernstein target price.
• Current price922.50 USDAs of April 14, 2026 close.
• Implied upside41%Based on a 1,300.00 USD target versus a 922.50 USD close.
• Market cap871,595 million USDDisclosed in report tables.
• Enterprise value908,192 million USDDisclosed in report tables.
• 2026E adjusted EPS33.96 USDDisclosed in financial summary table.
• 2027E adjusted EPS44.11 USDDisclosed in financial summary table.
• 2027E adjusted P/E20.9xDisclosed in financial summary table.
• Foundayo revenue upside scenario>2.0B USDThe report says above $2.0 billion is achievable; consensus is around 1.49B USD.

Impact & implications

For LLY, the first daily prescription data itself is weak, but because the coverage gap is clear, the market could underappreciate Foundayo’s true launch momentum if it overreads the number. If subsequent weekly data confirms improved capture, and sample and LillyDirect channel contributions become visible, Foundayo may strengthen Lilly’s competitive position in obesity and oral GLP-1 and support stronger-than-expected revenue with valuation rationale.

Risks

• Low or unstable IQVIA daily data capture could cause early-read missteps.
• It remains unclear how launch samples are incorporated into IQVIA data during the ramp period.
• The daily-to-weekly prescription expansion factor may differ from Wegovy pill.
• The total addressable obesity market may be lower than expected, affected by demand, regulation, pricing, competition, and fixed-dose combinations.
• If manufacturing expansion stalls, Lilly’s obesity business growth could be constrained.
• High-risk M&A or R&D execution could cause value impairment.
• Wegovy pill has existing brand awareness and may pressure Foundayo in oral obesity competition.

What to watch

• Foundayo's first IQVIA weekly data expected on April 17, 2026.
• Capture rate and scaling ratio between daily IQVIA and weekly IQVIA.
• Lilly IR disclosures on data coverage, sample handling, and channel inclusion methodology.
• The impact of LillyDirect and Amazon same-day delivery on prescription conversion and patient friction.
• Whether Foundayo’s first few weeks of TRx/NRx trends support 2026 revenue above $2.0 billion.
• Ongoing comparison with the early launch trajectory of Wegovy pill.